Agreement: I AgreeBody: Dear Editor,
Dr Ellen Grant, in her reply to my rapid response, claims that ‘the Collaborative Group on Hormonal Factors in Breast Cancer…found a significant nearly double increased risk of breast cancer with use of micronised progesterone (RR 1.93 (1.84-2.01).’ The figure that she quotes does not actually relate to micronised progesterone at all, but instead applies to the relative risk of oestrogen plus intermittent progestogen during 5-14 years of MHT use. As stated in my original rapid response, the relative risk of breast cancer for oestrogen-micronised progesterone combination for
1. Collaborative Group on Hormonal Factors in Breast Cancer. Type and Timing of menopausal therapy and breast cancer risk individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394 1159-68 [Supplementary appendix, page 45, Figure S15]
No competing Interests: YesThe following competing Interests: Electronic Publication Date: Monday, March 21, 2022 – 02:47Highwire Comment Subject: Risk of breast cancer with HRT depends on therapy type and durationWorkflow State: ReleasedFull Title: Risk of breast cancer with HRT depends on therapy type and duration: progesterone vs progestins
Highwire Comment Response to: Risk of breast cancer with HRT depends on therapy type and durationCheck this box if you would like your letter to appear anonymously:: Last Name: LewisFirst name and middle initial: PeterEmail: peter.lewis@ipn.com.auAddress: Vale Medical Practice, Brookvale, NSW 2100, AustraliaOccupation: GP with special interest in integrative medicineBMJ: Additional Article Info: Rapid response